Thymosin Alpha-1 Research: Trials, Immune Data & What the Studies Show
Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide naturally produced by the thymus gland that acts as an immunomodulator. It has been studied in over 30 clinical trials involving more than 11,000 human subjects, and is approved in several countries as Zadaxin for chronic viral infection and as a cancer adjunct — while remaining limited to off-label compounded research or orphan drug programmes in the United States.
Mechanism of action
Tα1 is a bidirectional modulator, not a blunt immune stimulant: it boosts defence mechanisms when the immune system is suppressed and dampens hyper-inflammation when it is overactive.
T-cell maturation — stimulates differentiation of stem cells into mature T-cells and balances CD3+/CD4+/CD8+ profiles.
Antiviral defence — increases natural killer (NK) cell and dendritic cell activity to target viral pathogens.
Antitumour activity — downregulates tumour cell growth and suppresses metastasis by enhancing cell-mediated antitumour immunity.
Inflammation control — lowers pro-inflammatory cytokines such as TNF-α while increasing regulatory signals such as IL-10, mitigating tissue damage.
Antioxidant protection — amplifies superoxide dismutase and catalase, decreasing cellular oxidative stress.
The studies
Tα1 has one of the largest human evidence bases of any compound in this catalogue. Note the pattern across it: broad all-comer endpoints often fail while pre-specified subgroups show clear effects — a signal that patient selection matters more than dose in this literature.
Critical care
TESTS trial — sepsis and critical illness
Whether Thymosin Alpha-1 reduces mortality in adult sepsis.
1,106 adult sepsis patients · multicentre, double-blind, placebo-controlled · 28-day all-cause mortality primary endpoint with pre-specified subgroups
- 1,106
- Participants
- No overall reduction
- 28-day all-cause mortality
- Elderly (60+) & diabetes
- Subgroup benefit
- The largest RCT conducted on Tα1 to date, enrolling 1,106 adult sepsis patients.
- Tα1 did not decrease broad 28-day all-cause mortality across the general study population.
- Pre-specified subgroup analyses revealed a distinct survival advantage in patients over 60 and individuals with diabetes — populations with baseline immune impairment.
Safety & evidence base
Comprehensive clinical safety and efficacy review
Pooled safety and efficacy of Tα1 across its entire clinical literature.
Comprehensive narrative review · over 30 separate trials · more than 11,000 human subjects across oncology, infection and autoimmunity
- 11,000+
- Subjects reviewed
- 30+
- Trials reviewed
- Zero reported
- Major adverse toxicities
- Investigators observed uniform evidence validating Tα1's safety profile and therapeutic efficacy in oncology, severe respiratory infections including COVID-19 variants, and autoimmune disorders.
- The peptide was well tolerated with zero major adverse toxicities reported across the pooled dataset.
- This breadth of human exposure is unusual for a compound sold in the research market.
Ageing & immunity
Counteracting age-related immune decline
Whether Tα1 offsets thymic involution and immunosenescence in older populations.
Focused research on thymic involution · naive T-cell output, vaccine antibody response and inflammatory-ageing markers
- Stimulated
- Naive T-cell production
- Improved
- Vaccine antibody response
- Refnot hybrid
- Combination candidate
- Addresses thymic involution — the gradual shrinkage of the thymus gland that drives immunosenescence with age.
- Tα1 mitigated age-related immune decay by stimulating naive T-cell production and improving antibody response to vaccines.
- The work also highlighted new therapeutic combinations, including the hybrid compound Refnot, designed to slow systemic inflammatory ageing.
Oncology
Chemotherapy and immunotherapy adjuvant support
Tα1 combined with multi-modality chemotherapy and checkpoint inhibitors.
Tα1 alongside chemotherapy and modern immunotherapies including CTLA-4 and PD-1/PD-L1 inhibitors · median survival and marrow suppression endpoints
- 38.4 months
- Median survival (Tα1 first)
- 8.0 months
- Median survival (control)
- Counteracted
- Marrow suppression
- Patients receiving Tα1 prior to immunotherapy achieved a median survival time of 38.4 months versus 8.0 months in the non-Tα1 control group.
- It counteracts chemotherapy-induced bone marrow suppression, supporting treatment tolerance.
- Mechanistic work focuses on priming cell-mediated antitumour immunity ahead of CTLA-4 and PD-1/PD-L1 blockade.
Chronic viral infection
Chronic hepatitis B and C remission trials
Synthetic Tα1 (thymalfasin) versus placebo in chronic viral liver infection.
Randomised clinical trials · synthetic thymalfasin versus placebo · virological response, HBeAg seroconversion and liver enzyme normalisation
- 40.6%
- Virological response (Tα1)
- 9.4%
- Virological response (control)
- Normalised
- Liver enzymes
- Tα1 drove a 40.6% virological response rate versus 9.4% in control groups.
- It facilitated significant HBeAg seroconversion and normalised liver enzyme levels.
- These results underpin the approvals of Zadaxin (thymalfasin) for chronic hepatitis in multiple countries outside the US.
Storage & handling
Thymosin Alpha-1 is supplied as a lyophilised powder. Keep sealed vials refrigerated or frozen, protected from light and moisture.
Reconstitute with bacteriostatic water directed slowly down the inner wall of the vial and swirl gently until clear. Do not shake — Tα1 is a 28-amino-acid chain and vulnerable to mechanical denaturation.
Store reconstituted solution at 2-8 °C and use within the stability window set by your lab's standard operating procedures.
All information on this page is provided for laboratory and educational reference only. Peptides Lab SA (PTY) Ltd supplies compounds strictly for in-vitro research use. Nothing here is medical advice, a dosing recommendation, or a claim of human safety or efficacy.